Schaeffer's Top Stock Picks for '25

Analyst Update: Clovis Oncology Inc, Calithera Biosciences Inc, and Gilead Sciences, Inc.

Analysts are weighing in on Clovis Oncology Inc (CLVS), Calithera Biosciences Inc (CALA), and Gilead Sciences, Inc. (GILD)

Oct 25, 2016 at 2:55 PM
facebook X logo linkedin


Analysts are weighing in on biotech stocks Clovis Oncology Inc (NASDAQ:CLVS)Calithera Biosciences Inc (NASDAQ:CALA), and Gilead Sciences, Inc. (NASDAQ:GILD). Here's a quick roundup of today's brokerage notes on CLVS, CALA, and GILD.

  • CLVS is 4.5% lower at $30.86, after Chardan Capital Markets initiated coverage on the stock with a "sell" rating and a $15 price target -- a discount of more than 50% to the equity's current value. An analyst at the firm cited "considerable risks" surrounding the company's ovarian cancer treatment, rucaparib, which is under priority review by the U.S. Food and Drug Administration (FDA). Specifically, he noted the drug "does not appear to show a clinical benefit over existing therapies." Traders appear to agree with this pessimistic outlook. At the moment, 12.7 million shares, or roughly 70% of Clovis Oncology Inc's available float, is wrapped up in short interest -- following an increase of 29% over the last two reporting periods, and marking a new record high.
  • CALA received a fresh "sell" rating and $1 price target from Citigroup, sending the shares plummeting 21.2% to $2.33 -- just off their new all-time low of $2.25, touched earlier. According to an analyst at the brokerage firm, Calithera Biosciences Inc lacks meaningful catalysts, and the company's spending points to the need for a partnership or fundraising to continue its current programs through the first half of 2017. CALA has been on a long downtrend since topping out north of $33 in December 2014 -- less than three months after the stock began trading publicly. The shares have shed nearly 70%% of their value in 2016 alone, so it's hardly surprising that short interest is elevated. These bearish bets currently account for 12.4% of the stock's total float, or 8.5 sessions' worth of trading, at CALA's average daily volume.

  • Jefferies raised its price target on GILD by $2 to $95, saying, "we believe the Street underappreciated the impressiveness of" the firm's Phase 2 trial data released last week. Gilead Sciences, Inc. stock is up 0.4% to $74.43 today, but still sits on a 31.5% year-over-year loss, after tapping a two-year low of $72.21 less than two weeks ago. These technical woes haven't dampened options traders' appetites for bullish bets, however. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), GILD holds a 10-day call/put volume ratio of 2.64 -- higher than 75% of all readings taken in the past year. 
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check
 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?